Andreen Niklas, Andersson Lars-Magnus, Sundell Nicklas, Gustavsson Lars, Westin Johan
Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden.
Infect Dis (Lond). 2022 Jul;54(7):508-513. doi: 10.1080/23744235.2022.2050422. Epub 2022 Mar 14.
The aim of this study was to compare the outcome of coronavirus disease 2019 (COVID-19) in hospitalised patients with chronic obstructive pulmonary disease (COPD) with the outcome in matched COVID-19 patients without COPD.
Sixty-three COPD patients hospitalised for acute COVID-19 from March through August 2020 were retrospectively identified and 63 hospitalised COVID-19 patients without COPD were selected and matched for age, gender and month of hospital admission.
COPD patients had a higher rate of comorbidities, especially cardiovascular disease, and a trend towards a higher 30-day mortality than control patients (35% vs. 22%). In the COPD group, high Charlson comorbidity index ( = 0.03) and previous cerebrovascular disease ( = 0.04) were associated with 30-day mortality in univariate analysis. Inhaled corticosteroids maintenance therapy was not associated with lower mortality.
COPD patients hospitalised for acute COVID-19 disease had significantly more comorbidities and a high risk of severe outcome and death within 30 days. Comorbidity, especially cardiovascular diseases, was associated with mortality among COPD patients.
本研究旨在比较2019冠状病毒病（COVID-19）住院慢性阻塞性肺疾病（COPD）患者与匹配的非COPD COVID-19患者的结局。
回顾性确定2020年3月至8月因急性COVID-19住院的63例COPD患者，并选取63例非COPD的住院COVID-19患者，根据年龄、性别和住院月份进行匹配。
COPD患者合并症发生率更高，尤其是心血管疾病，30天死亡率有高于对照患者的趋势（35%对22%）。在COPD组，单因素分析中高Charlson合并症指数（=0.03）和既往脑血管疾病（=0.04）与30天死亡率相关。吸入性糖皮质激素维持治疗与较低死亡率无关。
因急性COVID-19疾病住院的COPD患者合并症显著更多，30天内发生严重结局和死亡的风险高。合并症，尤其是心血管疾病，与COPD患者的死亡率相关。
